Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 121 results
Press release cover image

Sep 21, 2026

BIOCYTICS AND EREMID GENOMIC SERVICES COLLABORATE ON RESEARCH STUDY FOR NOVEL SINGLE-CELL TRANSCRIPTOMICS IMMUNE-BASED CANCER CELL THERAPY

HUNTERSVILLE, N.C., Sept. 18, 2026 /PRNewswire/ -- BioCytics, Inc., has engaged Eremid® Genomic Services to help sequence an autologous immune cell fraction that is the leading candidate of BioCytics' immune-based cancer cell therapy efforts. Eremid will perform single cell transcriptomic (scRNA-Seq) and TCR sequencing analysis of immune cells provided by BioCytics.BioCytics is focused on developing an autologous adaptive immune cell therapy that provides a personalized treatment for solid tumor
Press release cover image

Sep 18, 2026

NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed

ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug developmentThe investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into AsiaNAVER D2SF to strengthen its global healthcare founder community through its healthcare network and go-to-market expertiseSEOUL, South Korea, Sept. 18, 2026 /PRNewswire/ -- NAVER D2SF, NAVER's inhouse corporate venture arm, h
Press release cover image

Sep 17, 2026

Mission Bio Launches Tapestri® Triomics for Simultaneous DNA, RNA, and Protein Analysis at Single-Cell Resolution

New Tapestri® capability connects genotype, gene expression, and phenotype in the same cell, giving researchers a direct view of how genetic alterations shape cellular behavior.SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, a leader in single-cell multi-omics, today announced Tapestri® Triomics, a new expansion of the Tapestri Platform that simultaneously analyzes DNA, RNA, and protein in the same cell. By connecting genotype, gene expression, and phenotype at single-cell resolution,
Press release cover image

Sep 16, 2026

Linearis Labs Selected for Two Projects Under Terry Fox Research Institute's Digital Health Innovation Fund

QUÉBEC CITY, Sept. 16, 2026 /PRNewswire/ -- Linearis Labs has been selected to receive funding in two of the 14 pan-Canadian project teams announced today by the Terry Fox Research Institute (TFRI) under its Digital Health Innovation Fund, a program led by TFRI's Digital Health & Discovery Platform (DHDP). The 14 funded projects represent a combined investment of $40.9M and bring together 55 partners across Canada to advance AI-driven health data sharing for precision medicine.In its announc
Minimalist illustration of a microprotein and brain cell

Sep 16, 2026

Microprotein Atlas Links Brain Immune Cell Dysfunction to Alzheimer’s

Researchers at the Salk Institute have unveiled the first microprotein atlas of the human frontal cortex, shedding light on the relationship between microproteins and Alzheimer’s disease.This groundbreaking study, published in *Nature Aging*, highlights the often-overlooked role of microproteins—small proteins derived from small open reading frames (ORFs)—in neurodegenerative conditions. The atlas integrates advanced techniques such as transcriptomics, mass spectrometry, and AI-driven analysis t
Press release cover image

Sep 15, 2026

BostonGene Expands Scientific Collaboration with Leading Cancer Institute to Advance Breast Cancer Research

Applying Multimodal AI Analytics to Inform Patient Selection and Therapeutic Strategy in BRCA1/2-Mutated Breast CancersWALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI model for tumor and immune biology, today announced an expansion of its scientific collaboration with Dana-Farber Cancer Institute to deepen the understanding of the complex biological mechanisms driving BRCA1- and BRCA2-associated breast cancers. The collaboration applies BostonGene’s foundation model of t
Press release cover image

Sep 15, 2026

Therna Biosciences Releases Chronos, the Data Engine Behind its AI RNA Biologist

Therna's novel proprietary method generates millions of functional RNA measurements within a dynamic biological system, producing unique data sets from single experiments. A representative data set is now available to researchers and prospective partners.SAN FRANCISCO, Sept. 15, 2026 /PRNewswire/ -- Therna Biosciences, a biotechnology company whose AI RNA Biologist, RNA-Logix™, translates RNA language into medicines, today announced the launch of Chronos and the public release of one representat
Press release cover image

Sep 15, 2026

Mayo Clinic and Thermo Fisher Scientific launch Precure, LLC to identify signs of disease before symptoms appear

Pioneering initiative will generate data at the frontier of healthcare to help transform early biological signals into new opportunities for prevention, diagnosis and treatmentROCHESTER, Minn. and WALTHAM, Mass., Sept. 15, 2026 /PRNewswire/ -- Mayo Clinic today announced the launch of Precure, LLC, with founding partner Thermo Fisher Scientific, the world leader in serving science, to help transform how the life sciences community understands the biological changes that occur as people move from
Press release cover image

Sep 15, 2026

Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing to Advance Tissue-Resolved Liquid Biopsy Platform and Preeclampsia Lead Program

Financing co-led by Heal Capital and Ananda Impact Ventures will advance the Aitios® platform and ongoing validation of lead program to identify preeclampsia risk in a pregnancy’s first trimesterDr. Gordon Sanghera CBE FRS, co-founder and former CEO of Oxford Nanopore Technologies, joins Aitiologic’s advisory board and participates in the round as an investorDr. Rebecca Ertl, obstetrician-gynecologist and founder of a leading prenatal diagnostics center, appointed Chief Medical Officer VIENNA, S
A minimalist representation of DNA and data trends

Sep 15, 2026

Mayo Clinic teams with Thermo Fisher to form biomedical data group Precure

The Mayo Clinic has announced a collaboration with Thermo Fisher Scientific to establish Precure LLC, a new initiative aimed at creating a comprehensive biomedical dataset.This partnership focuses on generating extensive human multi-omics data, which includes proteomic, genomic, and clinical data. The primary objective is to identify early biological indicators of diseases before they are clinically diagnosed. By integrating molecular and clinical insights, the initiative aims to enhance the spe
Press release cover image

Sep 14, 2026

Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation

The Initiative Will Make Available 100,000 Disease-Specific Whole Genome Sequences Paired with Longitudinal Clinical Outcomes, with a Long-Term Goal of Reaching 1 Million GenomesCHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. The effort will create the first de-identified multimodal whole-genome sequencing (WGS) dataset built
Press release cover image

Sep 10, 2026

Helix Launches Whole Exome+® Sequencing for Patients with Rare and Unexplained Genetic Conditions

For patients with unexplained developmental delay, neurological conditions, and rare genetic disease, WES+ brings exome, mitochondrial, and chromosomal analysis together in a single orderSAN MATEO, Calif., Sept. 10, 2026 /PRNewswire/ -- Helix, the leading enterprise genomics platform, today announced the availability of Whole Exome+® Sequencing (WES+), a comprehensive diagnostic sequencing test now available to ordering providers nationwide.WES+ integrates four capabilities in a single order: br